NCT06778330

The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Fayoum University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to determine the efficacy of sildenafil (improve PAH) as an add-on therapy to dapagliflozin in the treatment of heart failure patients with secondary pulmonary arterial hypertension and compare the result with monotherapy dapagliflozin

Conditions

• Heart Failure NYHA Class II

Interventions

Type	Name	Description
DRUG	Dapagliflozin (DAPA)	Control group: receive dapagliflozin in addition to standard therapy
DRUG	Sildenafil	Test group: receive combination therapy of dapagliflozin and a small dose of sildenafil(25mg/day) in addition to standard therapy

Timeline

• Start date: 2025-01-20
• Primary completion: 2025-08-01
• Completion: 2025-08-01
• First posted: 2025-01-16
• Last updated: 2025-09-03

Locations

1 site across 1 country: Egypt